Influenza Vaccination

Dr. William Schaffner, MD, reviews evolving adult vaccination guidance and key opportunities to prevent severe disease in clinical practice.

The FDA approved an mRNA-based influenza vaccine mFLUSIVA for adults aged 50 years and older, with accelerated approval applying to adults aged 65 years and older.

New influenza and RSV research offers clinically relevant insights into vaccine performance and outbreak prevention. This roundup examines an investigational mRNA flu vaccine, rapid oseltamivir use in...

Recent studies address Long COVID surveillance, household transmission, updated vaccine effectiveness, kidney outcomes, and influenza vaccine coadministration.

ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.

A phase 3 RCT found mRNA-1010 superior to standard-dose vaccines for RT-PCR–confirmed influenza-like illness in adults ≥50.

A multisite surveillance study published in Pediatrics assessed trends and determinants of influenza antiviral use in hospitalized children across the United States before and during the late COVID-19...

This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.

New data describe durability of XBB.1.5 vaccine antibodies, platform-specific vaccine immunogenicity, CDC safety trust, and 2025 US uptake barriers.

Researchers compared high-dose versus standard-dose influenza vaccines in adults aged 65 to 79 years to determine whether enhanced immunogenicity translates into reduced severe clinical outcomes, including...